Li Y, Zeng X
Comb Chem High Throughput Screen. 2024; 28(1):146-165.
PMID: 39641162
DOI: 10.2174/0113862073271292231108113547.
Sun C, Zhan J, Li Y, Zhou C, Huang S, Zhu X
J Cell Mol Med. 2024; 28(8):e18348.
PMID: 38652105
PMC: 11037416.
DOI: 10.1111/jcmm.18348.
Dos Santos J, Moreno M, Teufel L, Chilibroste S, Keating S, Groh L
Cell Rep. 2024; 43(3):113932.
PMID: 38457336
PMC: 11000460.
DOI: 10.1016/j.celrep.2024.113932.
Gautam S, Batra S, Jain M
Mol Cancer. 2023; 22(1):118.
PMID: 37488598
PMC: 10367391.
DOI: 10.1186/s12943-023-01813-y.
Xiong Y, Kong X, Fang K, Sun G, Tu S, Wei Y
Mol Biol Rep. 2023; 50(9):7405-7419.
PMID: 37452900
DOI: 10.1007/s11033-023-08663-3.
Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death.
Li J, Yi X, Liu L, Wang X, Ai J
Apoptosis. 2023; 28(7-8):1198-1215.
PMID: 37184582
DOI: 10.1007/s10495-023-01851-3.
Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment.
Kwantwi L
Clin Exp Med. 2023; 23(7):3077-3091.
PMID: 37022584
DOI: 10.1007/s10238-023-01059-4.
Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis.
Yang W, Lu S, Peng L, Zhang Z, Zhang Y, Guo D
Front Immunol. 2023; 13:1085038.
PMID: 36618366
PMC: 9814966.
DOI: 10.3389/fimmu.2022.1085038.
Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z, Lv J, Dang Q, Liu L, Weng S, Wang L
Int J Biol Sci. 2022; 18(15):5607-5623.
PMID: 36263174
PMC: 9576504.
DOI: 10.7150/ijbs.76281.
Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine.
Wang X, Hua P, He C, Chen M
Acta Pharm Sin B. 2022; 12(9):3567-3593.
PMID: 36176912
PMC: 9513500.
DOI: 10.1016/j.apsb.2022.03.020.
Identification of RNA Modification-Associated Alternative Splicing Signature as an Independent Factor in Head and Neck Squamous Cell Carcinoma.
Liu J, Deng W, Xiao Z, Huang X, Lin M, Long Z
J Immunol Res. 2022; 2022:8976179.
PMID: 36157883
PMC: 9490063.
DOI: 10.1155/2022/8976179.
Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma.
Ren H, Zheng J, Cheng Q, Yang X, Fu Q
Front Genet. 2022; 13:900713.
PMID: 35957699
PMC: 9357940.
DOI: 10.3389/fgene.2022.900713.
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.
Gao W, Wang X, Zhou Y, Wang X, Yu Y
Signal Transduct Target Ther. 2022; 7(1):196.
PMID: 35725836
PMC: 9208265.
DOI: 10.1038/s41392-022-01046-3.
The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression.
Geller A, Shrestha R, Woeste M, Guo H, Hu X, Ding C
Nat Commun. 2022; 13(1):759.
PMID: 35140221
PMC: 8828725.
DOI: 10.1038/s41467-022-28407-4.
Ferroptosis Driver and Suppressor Independently Correlate With M1 and M2 Macrophage Infiltration in Head and Neck Squamous Cell Carcinoma.
Hu Z, Wen Y, Ma R, Chen L, Zeng X, Wen W
Front Cell Dev Biol. 2021; 9:727762.
PMID: 34527677
PMC: 8437260.
DOI: 10.3389/fcell.2021.727762.
